Clinical trials: Lower Urinary Tract Symptoms
Urinary Incontinence, Stress, Intrinsic Sphincter Deficiency
AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up
A single-center retrospective chart review of AdVance and AdVance XP subject data, combined with prospective follow-up of the same subjects to confirm continence, adverse event, and quality of life status.
- Trial name
- NCT01725984
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- American Medical Systems
Refractory Overactive Bladder
Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)
Evaluate the long-term clinical effectiveness and safety of the PINS Sacral Neuromodulation to patients with refractory Overactive Bladder.
- Trial name
- NCT02619721
- Testing
- PINS SNS
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Prostatic Hyperplasia
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
The primary objective of the study is to demonstrate the superiority of SL77.0499-10 10mg once daily over placebo and the non-inferiority versus tamsulosin hydrochloride after 12 weeks treatment in terms of the efficacy in…
- Trial name
- NCT00399464
- Testing
- alfuzosin
- Where
- Japan
- Volunteers
- 1,177 people
- Sponsor
- Sanofi
Overactive Bladder (OAB)
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.
- Trial name
- NCT03903094
- Testing
- Non-Interventional
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 6,295,279 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy…
- Trial name
- NCT07413692
- Testing
- EXOMIND (BTL-699-2) ActiveTreatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- BTL Industries Ltd.
Overactive Bladder, Urinary Incontinence
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment…
- Trial name
- NCT00439192
- Testing
- ELB245, Tolterodine
- Where
- 31 sites in Germany, Poland and 1 more
- Volunteers
- 275 people
- Sponsor
- elbion AG
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
A Randomized Triple-Blind Placebo-Controlled Study to Evaluate the Effects of a Supplement on Lower Urinary Tract Symptoms in Men.
This study aims to evaluate the effects of the ProstaThrive™ supplement on lower urinary tract symptoms (LUTS) in men. It is a 90-day virtual, randomized, placebo-controlled trial with 80 male participants aged 40 and above.
- Conditions
- Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction
- Trial name
- NCT06504472
- Testing
- ProstaThrive™ Supplement
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Optimale
Urge Urinary Incontinence, Urinary Frequency
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel.
- Trial name
- NCT00909181
- Testing
- Oxybutynin
- Where
- 55 sites in United States
- Volunteers
- 626 people
- Sponsor
- Antares Pharma Inc.
Stress Urinary Incontinence
Artificial Urinary Sphincter Clinical Outcomes
To evaluate the AMS 800 Artificial Urinary Sphincter (AUS) in men with primary stress urinary incontinence as measured by pad weight tests.
- Trial name
- AUSCO (NCT04088331)
- Testing
- AMS 800 Artificial Urinary Sphincter
- Where
- 18 sites in United States, Australia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation
Overactive Bladder
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects
This study is a Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Administration of DA-8010 in Healthy Subjects.
- Trial name
- NCT02821312
- Testing
- DA-8010
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Urinary Incontinence, Stress
Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.
SS-RBX will be used to evaluate pharmacodynamic changes in urethral function using a novel methodology
- Trial name
- NCT00141128
- Testing
- SS-RBX
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Pfizer
Overactive Bladder
The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder
The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial…
- Trial name
- NCT00553657
- Testing
- DETROL LA (drug)
- Where
- Australia
- Volunteers
- 55 people
- Sponsor
- GlaxoSmithKline
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms
RT-310 Dose Escalation BPH Study
RT-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects.
- Trial name
- NCT06136819
- Testing
- RT-310
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Resurge Therapeutics Inc.
Overactive Bladder
A Safety Extension Study of DR-OXY-301
This is a safety extension study of DR-OXY-301 at pre-selected sites. Subjects who complete the DR-OXY-301 study are eligible to participate. The duration of this extension study will be up to approximately 42 weeks.
- Trial name
- NCT00782769
- Testing
- Oxybutinyn Vaginal Ring 4mg, Oxybutinyn Vaginal Ring 6mg
- Where
- 35 sites in United States
- Volunteers
- 240 people
- Sponsor
- Duramed Research
Overactive Bladder (OAB)
Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder
The goal of this clinical trial is to study the NiNA System and how it works to treat overactive bladder. Up to 290 participants will be enrolled in the study in the USA and Australia.
- Trial name
- NOVASTIM (NCT07780786)
- Testing
- Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release
- Where
- 2 sites in United States, Australia
- Volunteers
- 290 people
- Sponsor
- NinaMED Pty Ltd
Urinary Bladder, Overactive
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).
- Trial name
- VOLT (NCT00463541)
- Testing
- solifenacin succinate
- Where
- 198 sites in United States
- Volunteers
- 2,225 people
- Sponsor
- Astellas Pharma Inc
Incontinence, Urinary
Clinical Study Investigating Safety and Performance of a New Urinary Intermittent Catheter in Healthy Volunteers
The aim of the study is to test the performance and safety of a newly developed intermittent catheter in healthy volunteers.
- Trial name
- NCT02965066
- Testing
- Coloplast Test Catheter, Coloplast Speedicath
- Where
- Denmark
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life.
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause (GSM), Quality of Life
- Trial name
- NCT07737782
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Mucosa Innovations, S.L.
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Endometriosis Related Pain, Overactive Bladder
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Researchers are looking for a new way to treat people suffering either from a condition where the bladder is unable to hold urine normally (overactive bladder), or a condition in which tissue similar to the tissue that normally…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04487431
- Testing
- BAY1817080, [14C]BAY1817080
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer